Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen

NCT00305838 is registered in ClinicalTrials.gov with Mount Vernon Cancer Centre at Mount Vernon Hospital as lead sponsor.

NCT NCT00305838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00305838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen
Lead sponsor
Mount Vernon Cancer Centre at Mount Vernon Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2004
Completion date
Not reported
Enrollment
200 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer